![]() ![]() Many vaccines have been developed in a remarkably short period of time and shown to be highly effective in phase III clinical trials and real life. As of March 2022, there have been more than 440 million reported cases of COVID-19, which have caused more than 6 million reported deaths worldwide. It was first diagnosed in late 2019 in Wuhan, China and has since spread over the globe, leading the WHO to declare a pandemic on March 11, 2020. Therefore, highly potent multimeric sACE2 may offer a promising treatment approach against SARS-CoV-2 infections.Ĭoronavirus disease 2019 (COVID-19) is a disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Finally, therapeutic treatment of sACE2(v1)-MoonTag provides protection against SARS-CoV-2 infection in an in vivo mouse model. Pseudoviruses bearing mutations for variants of concern, including delta and omicron, are also neutralized efficiently with multimeric sACE2. SunTag or MoonTag fused to a more potent sACE2 (v1) achieves a sub-nanomolar IC 50, comparable with clinical monoclonal antibodies. These systems are extremely effective in neutralizing SARS-CoV-2 in pseudoviral systems and in clinical isolates, perform better than the dimeric or trimeric sACE2, and exhibit greater than 100-fold neutralization efficiency, compared to monomeric sACE2. To address this challenge, multimeric sACE2 consisting of SunTag or MoonTag systems is developed. However, their success is limited by their relatively poor potency. Soluble ACE2 (sACE2) decoys are promising agents to inhibit SARS-CoV-2, as their efficiency is unlikely to be affected by escape mutations. ![]()
0 Comments
Leave a Reply. |